Hyeon-Su Im

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)

Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 115 citations · Full text

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Chung Ryul Oh, Sun‐Young Kong, Hyeon-Su Im et al. · BMC Cancer · 2019 · 65 citations · Full text

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)

H.S. Park, Beodeul Kang, Hong Jae Chon et al. · ESMO Open · 2021 · 38 citations · Full text

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

Kang‐Seo Park, Yong Sang Hong, Junyoung Choi et al. · BMB Reports · 2018 · 30 citations · Full text

Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study

Jeehee Pyo, Minsu Ock, Mina Lee et al. · BMC Palliative Care · 2021 · 26 citations · Full text